$ATNF
180 Life Sciences Corp.

2022 Q4 Form 10-Q Financial Statement

#000121390022071207 Filed on November 10, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.054M $3.419M $2.491M
YoY Change 102.94% -5.09% -213.64%
% of Gross Profit
Research & Development $585.7K $583.2K $1.972M
YoY Change -70.29% -5.23% -13.91%
% of Gross Profit
Depreciation & Amortization $37.60K $7.980K $16.81K
YoY Change 123.68% -77.17% -86.59%
% of Gross Profit
Operating Expenses $5.640M $4.055M $4.462M
YoY Change 26.4% -3.85% 4302.19%
Operating Profit -$4.055M
YoY Change -3.85%
Interest Expense $971.4K $7.348K $5.652M
YoY Change -82.81% -99.97% -604.44%
% of Operating Profit
Other Income/Expense, Net $0.00 -$17.43M -$159.1K
YoY Change -100.0% -141707.03% -156.69%
Pretax Income -$22.69M -$21.49M $1.030M
YoY Change -2303.29% -217.47% -154.15%
Income Tax -$942.8K -$6.620K
% Of Pretax Income -0.64%
Net Earnings -$21.74M -$21.49M $1.036M
YoY Change -2198.23% -217.44% -155.09%
Net Earnings / Revenue
Basic Earnings Per Share -$0.55
Diluted Earnings Per Share -$9.75 -$0.55 $30.52K
COMMON SHARES
Basic Shares Outstanding 40.46M shares 39.18M shares
Diluted Shares Outstanding 39.18M shares

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.970M $3.589M $8.225M
YoY Change -15.25% -69.3% 290.06%
Cash & Equivalents $6.970M $3.589M $8.225M
Short-Term Investments
Other Short-Term Assets $1.337M $53.20M $2.977M
YoY Change -55.07% 2633.9% 89.75%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $8.928M $6.515M $11.20M
YoY Change -20.29% -52.22% 178.98%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill $13.97M $36.99M
YoY Change
Intangibles $1.659M $1.565M $1.949M
YoY Change -14.88%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $10.72M $27.82M $51.51M
YoY Change -79.19% -45.91% -0.01%
TOTAL ASSETS
Total Short-Term Assets $8.928M $6.515M $11.20M
Total Long-Term Assets $10.72M $27.82M $51.51M
Total Assets $19.65M $34.34M $62.71M
YoY Change -68.67% -47.23% 12.93%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.801M $1.015M $586.6K
YoY Change 207.05% 57.88% -93.29%
Accrued Expenses $2.285M $2.092M $1.983M
YoY Change 15.21% -10.44% -56.98%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $84.76K $81.28K
YoY Change -100.0% 4.33% -96.99%
Long-Term Debt Due $1.309M $321.7K $1.828M
YoY Change -28.42% 15.18% 88.76%
Total Short-Term Liabilities $5.658M $4.725M $19.70M
YoY Change -71.28% -80.5% -8.22%
LONG-TERM LIABILITIES
Long-Term Debt $31.19K $31.52K $48.17K
YoY Change -35.25% -39.5% -57.66%
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $31.19K $31.52K $48.17K
YoY Change -35.25% -39.5% -57.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.658M $4.725M $19.70M
Total Long-Term Liabilities $31.19K $31.52K $48.17K
Total Liabilities $8.306M $8.261M $23.39M
YoY Change -64.49% -70.42% -7.35%
SHAREHOLDERS EQUITY
Retained Earnings -$107.4M -$85.67M -$68.68M
YoY Change 56.38%
Common Stock $375.00 $3.924K $3.404K
YoY Change -88.98%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.34M $26.08M $39.32M
YoY Change
Total Liabilities & Shareholders Equity $19.65M $34.34M $62.71M
YoY Change -68.67% -47.23% 12.93%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q4
OPERATING ACTIVITIES
Net Income -$21.74M -$21.49M $1.036M
YoY Change -2198.23% -217.44% -155.09%
Depreciation, Depletion And Amortization $37.60K $7.980K $16.81K
YoY Change 123.68% -77.17% -86.59%
Cash From Operating Activities -$2.927M -$3.596M -$5.028M
YoY Change -41.79% -10.15% 84.03%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.396M 5.488M 1.549M
YoY Change 312.88% -60.03% -118.52%
NET CHANGE
Cash From Operating Activities -2.927M -3.596M -5.028M
Cash From Investing Activities 0.000
Cash From Financing Activities 6.396M 5.488M 1.549M
Net Change In Cash 3.469M 1.891M -3.478M
YoY Change -199.73% -80.55% -294.89%
FREE CASH FLOW
Cash From Operating Activities -$2.927M -$3.596M -$5.028M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q3 atnf Offering Costs Allocated To Warrant Liabilities
OfferingCostsAllocatedToWarrantLiabilities
usd
CY2021Q1 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38105
dei Entity Registrant Name
EntityRegistrantName
180 LIFE SCIENCES CORP
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
90-1890354
dei Entity Address Address Line1
EntityAddressAddressLine1
3000 El Camino Real Bldg. 4
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 200
dei Entity Address City Or Town
EntityAddressCityOrTown
Palo Alto
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94306
dei City Area Code
CityAreaCode
(650)
dei Local Phone Number
LocalPhoneNumber
507-0669
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
ATNF
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40460494 shares
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
3588639 usd
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
8224508 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2926202 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2976583 usd
CY2022Q3 us-gaap Assets Current
AssetsCurrent
6514841 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
11201091 usd
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1564860 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1948913 usd
CY2022Q3 atnf Inprocess Research And Development
InprocessResearchAndDevelopment
12290516 usd
CY2021Q4 atnf Inprocess Research And Development
InprocessResearchAndDevelopment
12575780 usd
CY2022Q3 us-gaap Goodwill
Goodwill
13965715 usd
CY2021Q4 us-gaap Goodwill
Goodwill
36987886 usd
CY2022Q3 us-gaap Assets
Assets
34335932 usd
CY2021Q4 us-gaap Assets
Assets
62713670 usd
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1015244 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
586611 usd
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2092029 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1964580 usd
CY2022Q3 atnf Accrued Expenses Related Parties
AccruedExpensesRelatedParties
158467 usd
CY2021Q4 atnf Accrued Expenses Related Parties
AccruedExpensesRelatedParties
18370 usd
CY2022Q3 us-gaap Loans Payable Current
LoansPayableCurrent
321694 usd
CY2021Q4 us-gaap Loans Payable Current
LoansPayableCurrent
1828079 usd
CY2022Q3 atnf Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
84756 usd
CY2021Q4 atnf Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
81277 usd
CY2022Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1052807 usd
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
15220367 usd
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4724997 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
19699284 usd
CY2022Q3 atnf Loans Payable Non Current Portion
LoansPayableNonCurrentPortion
31522 usd
CY2021Q4 atnf Loans Payable Non Current Portion
LoansPayableNonCurrentPortion
48165 usd
CY2022Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3504046 usd
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
3643526 usd
CY2022Q3 us-gaap Liabilities
Liabilities
8260565 usd
CY2021Q4 us-gaap Liabilities
Liabilities
23390975 usd
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39246011 shares
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39246011 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
34035925 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
34035925 shares
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
3924 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3404 usd
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
115427474 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
107184137 usd
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-3689764 usd
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
817440 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85666267 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-68682286 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
26075367 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
39322695 usd
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34335932 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62713670 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
583177 usd
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
316473 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1688474 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
689217 usd
CY2022Q3 atnf Research And Development Related Parties
ResearchAndDevelopmentRelatedParties
53347 usd
CY2021Q3 atnf Research And Development Related Parties
ResearchAndDevelopmentRelatedParties
298879 usd
atnf Research And Development Related Parties
ResearchAndDevelopmentRelatedParties
158401 usd
atnf Research And Development Related Parties
ResearchAndDevelopmentRelatedParties
1287583 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3418628 usd
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3519605 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10405933 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8740067 usd
CY2021Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
82519 usd
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
5261 usd
us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
462081 usd
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
4055152 usd
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
4217476 usd
us-gaap Operating Expenses
OperatingExpenses
12258069 usd
us-gaap Operating Expenses
OperatingExpenses
11178948 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4055152 usd
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4217476 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-12258069 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-11178948 usd
CY2021Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
472677 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
927698 usd
CY2021Q3 us-gaap Other Income
OtherIncome
12308 usd
us-gaap Other Income
OtherIncome
12308 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
7348 usd
CY2021Q3 us-gaap Interest Expense
InterestExpense
5455 usd
us-gaap Interest Expense
InterestExpense
22117 usd
us-gaap Interest Expense
InterestExpense
130634 usd
CY2022Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1536 usd
CY2021Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-14201 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1495 usd
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-42279 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-9737 usd
CY2022Q3 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-18872850 usd
us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
-18872850 usd
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1449908 usd
CY2021Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-22043391 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-14167560 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
10342337 usd
atnf Change In Fair Value Of Accrued Issuable Equity
ChangeInFairValueOfAccruedIssuableEquity
9405 usd
atnf Offering Costs Allocated To Warrant Liabilities
OfferingCostsAllocatedToWarrantLiabilities
604118 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-17431826 usd
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22508720 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4725912 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-10198504 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21486978 usd
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
18291244 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16983981 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-21377452 usd
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-5612 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-16587 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-21486978 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
18296856 usd
us-gaap Net Income Loss
NetIncomeLoss
-16983981 usd
us-gaap Net Income Loss
NetIncomeLoss
-21360865 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-1871072 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-530817 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-4507204 usd
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
65018 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-23358050 usd
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
17766039 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21491185 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21295847 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.56
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.7
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.7
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39181736 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32727965 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35803504 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30491082 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39181736 shares
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
33709584 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35803504 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30491082 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
39322695 usd
CY2022Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
149718 usd
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
596467 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
1563713 usd
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-728081 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
40904512 usd
CY2022Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
60627 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
795052 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
2939284 usd
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1908051 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
42791424 usd
CY2022Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
60622 usd
CY2022Q3 atnf Issuance Of Prefunded Warrants
IssuanceOfPrefundedWarrants
2562265 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
155 usd
CY2022Q3 atnf Shares Issued In Connection With Offering
SharesIssuedInConnectionWithOffering
3407490 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions
611461 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-21486978 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1871072 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
26075367 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
30286869 usd
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
1941125 usd
CY2021Q1 atnf Shares Issued Upon Conversion Of180 Debt
SharesIssuedUponConversionOf180Debt
432383 usd
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10731070 usd
CY2021Q1 atnf Stock Issued During Period Value Offering Costs Allocated To Warrant Liabilities
StockIssuedDuringPeriodValueOfferingCostsAllocatedToWarrantLiabilities
604118 usd
CY2021Q1 atnf Warrants Issued In Connection With Private Offering Reclassified To Derivative Liabilities
WarrantsIssuedInConnectionWithPrivateOfferingReclassifiedToDerivativeLiabilities
-7294836 usd
CY2021Q1 atnf Stock Issued During Period Sharebased Compensation Common Stock
StockIssuedDuringPeriodSharebasedCompensationCommonStock
925404 usd
atnf Total Adjustments
TotalAdjustments
7016967 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9200830 usd
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1092399 usd
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16198585 usd
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
189348 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
22709295 usd
CY2021Q2 atnf Shares Issued To Settle Accounts Payable
SharesIssuedToSettleAccountsPayable
1973250 usd
CY2021Q2 atnf Stock Issued During Period Sharebased Compensation Common Stock
StockIssuedDuringPeriodSharebasedCompensationCommonStock
378659 usd
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
344095 usd
CY2021Q2 atnf Stock Based Compensation Correction Of An Error
StockBasedCompensationCorrectionOfAnError
363523 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-23459136 usd
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
406487 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
2716172 usd
CY2021Q3 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
13880000 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
1060500 usd
CY2021Q3 atnf Shares Issued In Connection With The Repayment Of Related Party Loans And Convertible Notes
SharesIssuedInConnectionWithTheRepaymentOfRelatedPartyLoansAndConvertibleNotes
851112 usd
CY2021Q3 atnf Stock Issued During Period Sharebased Compensation Common Stock
StockIssuedDuringPeriodSharebasedCompensationCommonStock
431996 usd
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
434979 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
18296856 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-530817 usd
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
37140799 usd
us-gaap Net Income Loss
NetIncomeLoss
-16983981 usd
us-gaap Net Income Loss
NetIncomeLoss
-21360865 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
270967 usd
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
2099582 usd
atnf Amortization Of Stock Options
AmortizationOfStockOptions
2002980 usd
atnf Amortization Of Stock Options
AmortizationOfStockOptions
1871473 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
18872850 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
71396 usd
us-gaap Other Depreciation And Amortization
OtherDepreciationAndAmortization
93139 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
338582 usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
927698 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-9737 usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-16587 usd
atnf Offering Costs Allocated To Warrant Liabilities
OfferingCostsAllocatedToWarrantLiabilities
604118 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
14167560 usd
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-10342337 usd
us-gaap Equity Fair Value Adjustment
EquityFairValueAdjustment
-9405 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-36340 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
443531 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
428632 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5458875 usd
atnf Increase Or Decrease In Accounts Payable Related Parties
IncreaseOrDecreaseInAccountsPayableRelatedParties
-211048 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
127449 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-799764 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
140097 usd
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-441403 usd
atnf Accrued Issuable Equitys
AccruedIssuableEquitys
52500 usd
atnf Total Adjustments
TotalAdjustments
7783151 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14343898 usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
26666200 usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
6499737 usd
atnf Proceeds From Exercise Of Prefunded Warrants
ProceedsFromExerciseOfPrefundedWarrants
-155 usd
atnf Offering Costs In Connection With Sale Of Common Stock And Warrants
OfferingCostsInConnectionWithSaleOfCommonStockAndWarrants
-529982 usd
atnf Offering Costs In Connection With Sale Of Common Stock And Warrants
OfferingCostsInConnectionWithSaleOfCommonStockAndWarrants
-2055130 usd
atnf Repayment Of Loans Payable Related Parties
RepaymentOfLoansPayableRelatedParties
1491986 usd
atnf Repayment Of Loans Payable Related Parties
RepaymentOfLoansPayableRelatedParties
306361 usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
431838 usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
10000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4477924 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
23862871 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
87037 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60283 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4635869 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9579256 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8224508 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2108544 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3588639 usd
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11687800 usd
us-gaap Interest Paid Net
InterestPaidNet
13423 usd
us-gaap Interest Paid Net
InterestPaidNet
31428 usd
atnf Warrants Issued In Connection With The Private Offering
WarrantsIssuedInConnectionWithThePrivateOffering
7294836 usd
atnf Shares Issued To Settle Accounts Payable
SharesIssuedToSettleAccountsPayable
1973250 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
1340184 usd
atnf Common Stock Issued Upon Exchange Of Notes Payable And Accrued Interest
CommonStockIssuedUponExchangeOfNotesPayableAndAccruedInterest
1283496 usd
atnf Shares And Warrants Issued For Alpha Settlement
SharesAndWarrantsIssuedForAlphaSettlement
1156177 usd
atnf Security Deposit Applied To Accounts Payable
SecurityDepositAppliedToAccountsPayable
7078 usd
atnf Exchange Of Common Stock Equivalents For Common Stock
ExchangeOfCommonStockEquivalentsForCommonStock
100 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 1 - BUSINESS ORGANIZATION AND NATURE OF OPERATIONS</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">180 Life Sciences Corp., formerly known as KBL Merger Corp. IV (“180LS”, or together with its subsidiaries, the “Company”), was a blank check company organized under the laws of the State of Delaware on September 7, 2016. The Company was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. On November 6, 2020 (“Closing Date”), a business combination was consummated following a special meeting of stockholders, where the stockholders of the Company considered and approved, among other matters, a proposal to adopt a Business Combination Agreement. Pursuant to the Business Combination Agreement, KBL Merger Sub, Inc. merged with 180 Life Corp. (f/k/a 180 Life Sciences Corp.) (“<span style="text-decoration:underline">180</span>”), with 180 continuing as the surviving entity and becoming a wholly-owned subsidiary of the Company (“the Business Combination”). References to “KBL” refer to the Company prior to the November 6, 2020 business combination.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Company is a clinical stage biotechnology company focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis and other inflammatory diseases, where anti-TNF therapy will provide a clear benefit to patients, by employing innovative research, and, where appropriate, combination therapy. We have three product development platforms:</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">fibrosis and anti-tumor necrosis factor (“TNF”);</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.25in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">drugs which are derivatives of cannabidiol (“CBD”); and</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-indent: -0.25in"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="vertical-align: top"> <td style="width: 48px"> </td> <td style="width: 24px"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">alpha 7 nicotinic acetylcholine receptor (“α7nAChR”).</span></td></tr> </table>
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
9200830 usd
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85666267 usd
atnf Working Capital
WorkingCapital
1789844 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.7
CY2022Q3 us-gaap Reporting Unit Amount Of Fair Value In Excess Of Carrying Amount
ReportingUnitAmountOfFairValueInExcessOfCarryingAmount
44974955 usd
CY2022Q3 us-gaap Other Assets Current
OtherAssetsCurrent
53200000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>Use of Estimates</b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, together with amounts disclosed in the related notes to the condensed consolidated financial statements. The Company’s significant estimates and assumptions used in these condensed consolidated financial statements include, but are not limited to, the collectability of an insurance claims receivable, the fair value of financial instruments warrants, options and equity shares, the valuation of stock-based compensation, and the estimates and assumptions related to impairment analysis of goodwill and other intangible assets.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Certain of the Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and may cause actual results to differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-1871072 usd
CY2021Q3 us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-530817 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
-4507204 usd
us-gaap Other Comprehensive Income Loss Before Tax
OtherComprehensiveIncomeLossBeforeTax
65018 usd
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-14031 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-14151 usd
CY2021Q3 us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-218834 usd
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-200264 usd
CY2022Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.67
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
26102105 usd
CY2022Q3 us-gaap Shares Issued
SharesIssued
39251286 shares
CY2022Q3 us-gaap Excess Stock Shares Outstanding
ExcessStockSharesOutstanding
39246011 shares
atnf Voting Shares
VotingShares
5275 shares
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.23
CY2022Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
8200000 usd
CY2022Q3 us-gaap Amount Of Impairment To Carrying Amount Of Regulatory Assets
AmountOfImpairmentToCarryingAmountOfRegulatoryAssets
18872850 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
18872850 usd
us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
7608238 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-21486978 usd
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
18296856 usd
us-gaap Net Income Loss
NetIncomeLoss
-16983981 usd
us-gaap Net Income Loss
NetIncomeLoss
-21360865 usd
CY2021Q3 atnf Decrease In Fair Value Of Dilutive Warrants
DecreaseInFairValueOfDilutiveWarrants
10487783 usd
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-21486978 usd
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
7809073 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-16983981 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-21360865 usd
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39181736 shares
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32727965 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35803504 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30491082 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
182727 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
798892 shares
CY2021Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
981619 shares
CY2022Q3 us-gaap Incremental Common Shares Attributable To Participating Nonvested Shares With Non Forfeitable Dividend Rights
IncrementalCommonSharesAttributableToParticipatingNonvestedSharesWithNonForfeitableDividendRights
39181736 shares
CY2021Q3 us-gaap Incremental Common Shares Attributable To Participating Nonvested Shares With Non Forfeitable Dividend Rights
IncrementalCommonSharesAttributableToParticipatingNonvestedSharesWithNonForfeitableDividendRights
33709584 shares
us-gaap Incremental Common Shares Attributable To Participating Nonvested Shares With Non Forfeitable Dividend Rights
IncrementalCommonSharesAttributableToParticipatingNonvestedSharesWithNonForfeitableDividendRights
35803504 shares
us-gaap Incremental Common Shares Attributable To Participating Nonvested Shares With Non Forfeitable Dividend Rights
IncrementalCommonSharesAttributableToParticipatingNonvestedSharesWithNonForfeitableDividendRights
30491082 shares
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.56
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.7
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
1085000 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20545105 shares
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8962250 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20545105 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
13219908 shares
CY2022Q3 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
378009 usd
CY2021Q4 us-gaap Accrued Insurance Current And Noncurrent
AccruedInsuranceCurrentAndNoncurrent
2151487 usd
us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
601265 usd
CY2021 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
644513 usd
us-gaap Increase Decrease In Insurance Settlements Receivable
IncreaseDecreaseInInsuranceSettlementsReceivable
1836940 usd
us-gaap Professional Fees
ProfessionalFees
38311 usd
CY2021 us-gaap Professional Fees
ProfessionalFees
80783 usd
CY2022Q3 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
46059 usd
CY2021Q4 us-gaap Value Added Tax Receivable
ValueAddedTaxReceivable
24411 usd
CY2022Q3 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
25618 usd
CY2021Q4 us-gaap Accrued Income Taxes
AccruedIncomeTaxes
25634 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
49755 usd
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2926202 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2976583 usd
atnf Consulting Fee
ConsultingFee
402315 usd
CY2021 atnf Consulting Fee
ConsultingFee
548281 usd
us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
26738 usd
CY2021 us-gaap Professional And Contract Services Expense
ProfessionalAndContractServicesExpense
252973 usd
atnf Accrued Legal Fees
AccruedLegalFees
218217 usd
CY2021 atnf Accrued Legal Fees
AccruedLegalFees
300000 usd
us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
1236014 usd
CY2021 us-gaap Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
725569 usd
us-gaap Research And Development Expense Software Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost
168172 usd
CY2021 us-gaap Research And Development Expense Software Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost
91737 usd
us-gaap Interest And Debt Expense
InterestAndDebtExpense
33523 usd
CY2021 us-gaap Interest And Debt Expense
InterestAndDebtExpense
25433 usd
atnf Other Accrued Liabilities
OtherAccruedLiabilities
7050 usd
CY2021 atnf Other Accrued Liabilities
OtherAccruedLiabilities
20587 usd
atnf Accrued Liabilities
AccruedLiabilities
2092029 usd
CY2021 atnf Accrued Liabilities
AccruedLiabilities
1964580 usd
CY2022Q3 atnf Accrued Expenses Related Parties
AccruedExpensesRelatedParties
158467 usd
CY2021Q4 atnf Accrued Expenses Related Parties
AccruedExpensesRelatedParties
18370 usd
CY2021Q4 us-gaap Derivative Liabilities
DerivativeLiabilities
15220367 usd
CY2022Q1 atnf Change In Fair Values Of Derivative Liabilities
ChangeInFairValuesOfDerivativeLiabilities
5230114 usd
CY2022Q1 us-gaap Derivative Liabilities
DerivativeLiabilities
9990253 usd
CY2022Q2 atnf Change In Fair Values Of Derivative Liabilities
ChangeInFairValuesOfDerivativeLiabilities
7487538 usd
CY2022Q2 us-gaap Derivative Liabilities
DerivativeLiabilities
2502715 usd
CY2022Q3 atnf Change In Fair Values Of Derivative Liabilities
ChangeInFairValuesOfDerivativeLiabilities
1449908 usd
CY2022Q3 us-gaap Derivative Liabilities
DerivativeLiabilities
1052807 usd
atnf Fair Value Assumption Expected Dividend Rate
FairValueAssumptionExpectedDividendRate
0 pure
CY2022Q3 us-gaap Share Price
SharePrice
0.67
CY2021 atnf Expected Volatility
ExpectedVolatility
0.985 pure
CY2021 atnf Fair Value Assumption Expected Dividend Rate
FairValueAssumptionExpectedDividendRate
0 pure
CY2021Q4 us-gaap Share Price
SharePrice
3.9
CY2021Q4 atnf Number Of Warrants Outstanding
NumberOfWarrantsOutstanding
11153908 shares
CY2021Q4 atnf Weighted Average Exercises Price Beginning Balance
WeightedAverageExercisesPriceBeginningBalance
9.06
atnf Weighted Average Remaining Life In Years Beginning Balance
WeightedAverageRemainingLifeInYearsBeginningBalance
P4Y1M6D
atnf Number Of Warrants Issued
NumberOfWarrantsIssued
8764152 shares
atnf Weighted Average Exercise Price Beginning Balance
WeightedAverageExercisePriceBeginningBalance
0.74
atnf Weighted Average Remaining Life In Years Issued
WeightedAverageRemainingLifeInYearsIssued
P5Y3M18D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1750067 usd
CY2022Q3 atnf Number Of Warrants Exercised
NumberOfWarrantsExercised
-1547076 shares
atnf Weighted Average Exercise Price Exercisedin Dollars Per Share
WeightedAverageExercisePriceExercisedinDollarsPerShare
0.0001
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
-1028651 usd
CY2022Q3 atnf Number Of Warrants Outstanding
NumberOfWarrantsOutstanding
18370984 shares
atnf Interest Expense On Loans
InterestExpenseOnLoans
30899 usd
CY2022Q3 atnf Weighted Average Exercises Price Beginning Balance
WeightedAverageExercisesPriceBeginningBalance
5.77
atnf Weighted Average Remaining Life In Years Outstanding Balance
WeightedAverageRemainingLifeInYearsOutstandingBalance
P3Y9M18D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
721417 shares
CY2022Q3 atnf Number Of Warrants Exercisable Balance
NumberOfWarrantsExercisableBalance
12238908 shares
CY2022Q3 atnf Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice1
8.13
atnf Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm
P3Y
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
721417 usd
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
18370984 shares
atnf Warrants Exercisable Weighted Average Remaining Life In Years
WarrantsExercisableWeightedAverageRemainingLifeInYears
P3Y3M18D
atnf Warrants Exercisable Number Of Shares
WarrantsExercisableNumberOfShares
12238908 shares
CY2021Q4 us-gaap Debt Instrument Annual Principal Payment
DebtInstrumentAnnualPrincipalPayment
1876244 usd
us-gaap Debt Instrument Periodic Payment
DebtInstrumentPeriodicPayment
1491986 usd
us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
19042 usd
us-gaap Debt Instrument Increase Decrease Other Net
DebtInstrumentIncreaseDecreaseOtherNet
12000 usd
CY2022Q3 us-gaap Debt Instrument Annual Principal Payment
DebtInstrumentAnnualPrincipalPayment
353216 usd
CY2021Q4 us-gaap Loans Payable Current
LoansPayableCurrent
1828079 usd
CY2022Q3 us-gaap Loans Payable Current
LoansPayableCurrent
321694 usd
CY2021Q4 us-gaap Long Term Loans Payable
LongTermLoansPayable
48165 usd
CY2022Q3 us-gaap Long Term Loans Payable
LongTermLoansPayable
31522 usd
CY2022Q3 us-gaap Due From Other Related Parties
DueFromOtherRelatedParties
481321 usd
CY2022Q3 us-gaap Debt Instrument Periodic Payment Principal
DebtInstrumentPeriodicPaymentPrincipal
2692 usd
CY2021Q4 us-gaap Notes Payable Related Parties Current And Noncurrent
NotesPayableRelatedPartiesCurrentAndNoncurrent
81277 usd
atnf Reclass From Loans Payable
ReclassFromLoansPayable
5000 usd
atnf Effect Of Foreign Exchange Rate
EffectOfForeignExchangeRate
1521 usd
CY2022Q3 us-gaap Notes Payable Related Parties Current And Noncurrent
NotesPayableRelatedPartiesCurrentAndNoncurrent
84756 usd
atnf Commitments Combined Amount
CommitmentsCombinedAmount
3178025 usd
atnf Additional Sum Of Amount
AdditionalSumOfAmount
2721036 usd
us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
32914 usd
atnf Accrued Interest Payable Related Party
AccruedInterestPayableRelatedParty
16676 usd
CY2021 us-gaap Debt Instrument Increase Accrued Interest
DebtInstrumentIncreaseAccruedInterest
24212 usd
CY2021 atnf Accrued Interest Payable Related Party
AccruedInterestPayableRelatedParty
812 usd
CY2021Q3 us-gaap Loss Contingency Damages Awarded Value
LossContingencyDamagesAwardedValue
11286570 usd
us-gaap Legal Fees
LegalFees
218217 usd
CY2022Q1 atnf Debt Principal Amount
DebtPrincipalAmount
371178 usd
CY2022Q1 atnf Debt Additional Amount
DebtAdditionalAmount
300000 usd
CY2022Q3 us-gaap Interest Receivable
InterestReceivable
6776686 usd
atnf Commitments Combined Amount
CommitmentsCombinedAmount
4395000 cad
CY2022Q3 us-gaap Insurance Settlements Receivable
InsuranceSettlementsReceivable
1836940 usd
us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
12000 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P24M
CY2022Q3 atnf Stockbased Compensation Expense Related To Amortization
StockbasedCompensationExpenseRelatedToAmortization
6075 usd
atnf Stockbased Compensation Expense Related To Amortization
StockbasedCompensationExpenseRelatedToAmortization
20250 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
12000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
5000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
4.05
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
7000 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.05
us-gaap Allocated Share Based Compensation Expense Net Of Tax
AllocatedShareBasedCompensationExpenseNetOfTax
28350 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
P1Y3M
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2741000 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.77
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P9Y4M24D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
70500 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
518121 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.36
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3259121 shares
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.23
atnf Weighted Average Remaining Term
WeightedAverageRemainingTerm
P8Y9M18D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1660057 shares
CY2022Q3 atnf Weighted Average Exercise Price Exercisable Ending
WeightedAverageExercisePriceExercisableEnding
4.16
atnf Weighted Average Remaining Term Yrs Exercisable Ending
WeightedAverageRemainingTermYrsExercisableEnding
P8Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q3 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
141791 usd
CY2021Q4 atnf Accrued Expenses Related Parties
AccruedExpensesRelatedParties
18370 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0288 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.91 pure
CY2022Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
3259121 shares
atnf Stock Options Exercisable Weighted Average Remainings Life In Years
StockOptionsExercisableWeightedAverageRemainingsLifeInYears
P8Y8M12D
atnf Stock Options Exercisable Number Of Share
StockOptionsExercisableNumberOfShare
1660057 shares
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
672083 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2273947 usd
CY2022Q3 atnf General And Administrative Expenses
GeneralAndAdministrativeExpenses
584237 usd
atnf General And Administrative Expenses
GeneralAndAdministrativeExpenses
1959919 usd
CY2022Q3 atnf Research And Development Expenses
ResearchAndDevelopmentExpenses
87846 usd
atnf Research And Development Expenses
ResearchAndDevelopmentExpenses
314028 usd
CY2021Q3 atnf General And Administrative Expenses
GeneralAndAdministrativeExpenses
434979 usd
atnf General And Administrative Expenses
GeneralAndAdministrativeExpenses
1871473 usd
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4827266 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P2Y3M18D
CY2022Q3 atnf Aggregate Shares
AggregateShares
3500000 shares
srt Financing Receivable Writeoff After Recovery To Average Outstanding Percent
FinancingReceivableWriteoffAfterRecoveryToAverageOutstandingPercent
0.0999 pure
atnf Prefunded Warrant Shares
PrefundedWarrantShares
1547076 shares
atnf Prefunded Warrant Exercised
PrefundedWarrantExercised
155 usd
atnf Pre Funded Warrants Un Exercised
PreFundedWarrantsUnExercised
1085000 shares
CY2022Q3 atnf Accrued Expenses Related Parties
AccruedExpensesRelatedParties
158467 usd
CY2022Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
16676 usd
CY2022Q3 atnf Loans Payable Related Parties
LoansPayableRelatedParties
84756 usd
CY2021Q4 atnf Loans Payable Related Parties
LoansPayableRelatedParties
81277 usd
CY2022Q3 atnf Research And Development Expenses Related Parties
ResearchAndDevelopmentExpensesRelatedParties
53347 usd
CY2021Q3 atnf Research And Development Expenses Related Parties
ResearchAndDevelopmentExpensesRelatedParties
298879 usd
atnf Research And Development Expenses Related Parties
ResearchAndDevelopmentExpensesRelatedParties
158401 usd
atnf Research And Development Expenses Related Parties
ResearchAndDevelopmentExpensesRelatedParties
1287583 usd
CY2022Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
0 usd
CY2021Q3 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
82519 usd
CY2021Q3 atnf Related Party Interest Expense Associated With Convertible Notes
RelatedPartyInterestExpenseAssociatedWithConvertibleNotes
3633 usd
atnf Related Party Interest Expense Associated With Convertible Notes
RelatedPartyInterestExpenseAssociatedWithConvertibleNotes
11380 usd
CY2021Q3 atnf Interest Expense On Loans
InterestExpenseOnLoans
10567 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
5261 usd
us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
462081 usd
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1536 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
1495 usd
CY2021Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
14201 usd
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
42279 usd
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q3 atnf Preferred Stock Value1
PreferredStockValue1
usd
CY2022Q3 atnf Preferred Stock Value2
PreferredStockValue2
usd
CY2022Q3 us-gaap Other Selling General And Administrative Expense
OtherSellingGeneralAndAdministrativeExpense
usd
CY2022Q3 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
usd
us-gaap Other Income
OtherIncome
usd
CY2022Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2021Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
CY2021Q3 us-gaap Gain Loss On Sales Of Assets And Asset Impairment Charges
GainLossOnSalesOfAssetsAndAssetImpairmentCharges
usd
CY2022Q3 atnf Change In Fair Value Of Accrued Issuable Equity
ChangeInFairValueOfAccruedIssuableEquity
usd
CY2021Q3 atnf Change In Fair Value Of Accrued Issuable Equity
ChangeInFairValueOfAccruedIssuableEquity
usd
atnf Change In Fair Value Of Accrued Issuable Equity
ChangeInFairValueOfAccruedIssuableEquity
usd
CY2022Q3 atnf Offering Costs Allocated To Warrant Liabilities
OfferingCostsAllocatedToWarrantLiabilities
usd
atnf Offering Costs Allocated To Warrant Liabilities
OfferingCostsAllocatedToWarrantLiabilities
usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2021Q2 atnf Stock Issued Impact Of Transfer Agent Reconciliation
StockIssuedImpactOfTransferAgentReconciliation
usd
CY2021Q3 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
usd
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
usd
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
usd
atnf Offering Costs Allocated To Warrant Liabilities
OfferingCostsAllocatedToWarrantLiabilities
usd
us-gaap Equity Fair Value Adjustment
EquityFairValueAdjustment
usd
atnf Increase Or Decrease In Accounts Payable Related Parties
IncreaseOrDecreaseInAccountsPayableRelatedParties
usd
atnf Accrued Issuable Equitys
AccruedIssuableEquitys
usd
us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
usd
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
usd
atnf Proceeds From Exercise Of Prefunded Warrants
ProceedsFromExerciseOfPrefundedWarrants
usd
us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
atnf Common Stock Issued Upon Exchange Of Notes Payable And Accrued Interest
CommonStockIssuedUponExchangeOfNotesPayableAndAccruedInterest
usd
atnf Shares And Warrants Issued For Alpha Settlement
SharesAndWarrantsIssuedForAlphaSettlement
usd
atnf Security Deposit Applied To Accounts Payable
SecurityDepositAppliedToAccountsPayable
usd
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
shares
CY2022Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
shares
atnf Warrants Issued In Connection With The Private Offering
WarrantsIssuedInConnectionWithThePrivateOffering
usd
atnf Shares Issued To Settle Accounts Payable
SharesIssuedToSettleAccountsPayable
usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
shares
atnf Exchange Of Common Stock Equivalents For Common Stock
ExchangeOfCommonStockEquivalentsForCommonStock
usd
CY2022Q3 atnf Decrease In Fair Value Of Dilutive Warrants
DecreaseInFairValueOfDilutiveWarrants
usd
atnf Decrease In Fair Value Of Dilutive Warrants
DecreaseInFairValueOfDilutiveWarrants
usd
atnf Decrease In Fair Value Of Dilutive Warrants
DecreaseInFairValueOfDilutiveWarrants
usd
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
shares
CY2021 us-gaap Increase Decrease In Insurance Settlements Receivable
IncreaseDecreaseInInsuranceSettlementsReceivable
usd
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
shares
atnf Weighted Average Remaining Life In Years Exercised
WeightedAverageRemainingLifeInYearsExercised
CY2022Q3 atnf Number Of Warrants Cancelled
NumberOfWarrantsCancelled
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2022Q3 atnf Number Of Warrants Expiredin Dollars Per Share
NumberOfWarrantsExpiredinDollarsPerShare
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
us-gaap Debt Instrument Decrease Forgiveness
DebtInstrumentDecreaseForgiveness
usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
atnf Weighted Average Remaining Term Yrs Grantedin Shares
WeightedAverageRemainingTermYrsGrantedinShares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
usd
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
usd
atnf Number Of Options Expired
NumberOfOptionsExpired
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
atnf Weighted Average Remaining Term Yrs Expired
WeightedAverageRemainingTermYrsExpired
atnf Intrinsic Value Expired
IntrinsicValueExpired
usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
atnf Weighted Average Remaining Term Yrs Forfeited
WeightedAverageRemainingTermYrsForfeited
atnf Intrinsic Value Forfeited
IntrinsicValueForfeited
usd
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
usd
CY2022Q3 atnf Intrinsic Value Exercisable Ending
IntrinsicValueExercisableEnding
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001690080

Files In Submission

Name View Source Status
0001213900-22-071207-index-headers.html Edgar Link pending
0001213900-22-071207-index.html Edgar Link pending
0001213900-22-071207.txt Edgar Link pending
0001213900-22-071207-xbrl.zip Edgar Link pending
atnf-20220930.xsd Edgar Link pending
f10q0922ex31-1_180lifesci.htm Edgar Link pending
f10q0922ex31-2_180lifesci.htm Edgar Link pending
f10q0922ex32-1_180lifesci.htm Edgar Link pending
f10q0922ex32-2_180lifesci.htm Edgar Link pending
f10q0922_180lifesci.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_001.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
atnf-20220930_cal.xml Edgar Link unprocessable
f10q0922_180lifesci_htm.xml Edgar Link completed
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
atnf-20220930_pre.xml Edgar Link unprocessable
atnf-20220930_def.xml Edgar Link unprocessable
atnf-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable